News Medical on MSN
Study offers a practical strategy to enhance effectiveness of immune checkpoint inhibitors
Cancer immunotherapy has transformed modern oncology by harnessing body's own immune system to combat malignant disease.
The DEPEND study demonstrates that checkpoint inhibitor nivolumab (Opdivo®) works best with high levels of PD-L1 biomarker, but does not work well with low levels of PD-L1 Multikine* is uniquely ...
A new analysis of real-world data show that just as in solid tumors, higher tumor mutational burden (TMB) and PD-L1 expression in blood cancers are linked to less-optimistic prognoses. Their ...
Treatment responses to Xalkori were not affected by PD-L1 expression in patients with advanced non-small cell lung cancer and ROS1 rearrangements. Patients with advanced non-small cell lung cancer ...
Cancer immunotherapy has transformed modern oncology by harnessing the body's own immune system to combat malignant disease.
Factors Associated With Implementation of Biomarker Testing and Strategies to Improve Its Clinical Uptake in Cancer Care: Systematic Review Using Theoretical Domains Framework Observational studies or ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced that in a recent meeting the U.S. Food and Drug Administration (FDA) concurred with the Company’s approach to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results